双叶式主动脉瓣患者行快速部署主动脉瓣置换术:单中心经验
本研究基于维也纳医科大学2010年5月至2020年12月的机构数据库,比较了107例双叶式主动脉瓣(BAV)患者与690例三叶式主动脉瓣(TAV)患者行快速部署主动脉瓣置换术(RD-AVR)的结局。BAV组5年中度至重度瓣周反流累积发生率为10.7%,TAV组为3.9%(P=0.057);BAV组长期生存率显著优于TAV组(log-rank检验P=0.002)。结论认为RD-AVR可用于BAV患者且医疗结局令人信服,但长期随访观察到中度至重度瓣周反流频率有增加趋势,推荐采用与三叶式瓣膜不同、具有明确特定技术和解剖考量与要求的手术入路。
要点
- BAV组5年中度至重度瓣周反流累积发生率为10.7%(95%CI 4.2-20.7%),TAV组为3.9%(95%CI 2.4-6.1%),P=0.057。
- BAV组5年因非结构性瓣膜功能障碍行瓣膜切除再手术率为2.8%(95%CI 0.5-8.8%),TAV组为1.9%(95%CI 1.0-3.2%),P=0.89。
- BAV组长期总体生存率5年为92%(95%CI 81-97%)、10年为88%(95%CI 73-95%),显著优于TAV组(log-rank检验P=0.002)。
核心结论
- RD-AVR可用于BAV患者且医疗结局令人信服,但长期随访观察到中度至重度瓣周反流频率有增加趋势。
- 作者推荐对BAV采用与三叶式瓣膜不同、具有明确特定技术和解剖考量与要求的手术入路。
研究设计与样本
- 单中心机构数据库分析,纳入2010年5月至2020年12月在维也纳医科大学连续接受RD-AVR的患者。
- 比较原生BAV患者与原生TAV对照组,排除再次主动脉瓣置换者。
- 评估术前特征、手术结局、长期生存和临床事件。
主要发现
- 共816例患者接受RD-AVR,其中BAV组107例,平均年龄68岁(标准差8);TAV组690例,平均年龄74岁(标准差7);BAV组显著年轻于TAV组(P<0.001)。
- 合并手术BAV组44例(41.1%),TAV组339例(49.1%),P=0.123;升主动脉手术BAV组24例(22.4%),对照组29例(4.2%),P<0.001。
- 5年中度至重度瓣周反流累积发生率BAV组10.7%(95%CI 4.2-20.7%),TAV组3.9%(95%CI 2.4-6.1%),P=0.057。
- 5年因非结构性瓣膜功能障碍行瓣膜切除再手术率BAV组2.8%(95%CI 0.5-8.8%),TAV组1.9%(95%CI 1.0-3.2%),P=0.89。
- BAV组长期总体生存率5年92%(95%CI 81-97%)、10年88%(95%CI 73-95%),显著优于TAV组(log-rank检验P=0.002)。
临床怎么用
- 作者推荐对BAV患者采用与三叶式瓣膜不同、具有明确特定技术和解剖考量与要求的手术入路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The benefit of rapid-deployment aortic valve replacement (RD-AVR) in patients with a bicuspid aortic valve (BAV) is controversial due to aortic root asymmetry and potential increased risk for valve dislocation and paravalvular leak. This study aimed to analyse the outcomes of surgical aortic valve replacement with a rapid-deployment bioprosthesis in patients with a BAV. METHODS: Between May 2010 and December 2020, all consecutive patients who underwent RD-AVR at the Medical University of Vienna were included in our institutional database. Assessment of preoperative characteristics, operative outcomes, long-term survival and clinical events was performed. The outcomes of patients presenting with a native BAV were compared with a control group of patients with native tricuspid valve (TAV); reoperative aortic valve replacements were excluded. RESULTS: Out of 816 patients, who underwent RD-AVR at our institution, 107 patients with a BAV, mean age 68 (standard deviation: 8) years, were compared with a control group of 690 patients with a TAV, mean age 74 (standard deviation: 7) years; patients presenting with a BAV were significantly younger than patients with a TAV (P < 0.001). Concomitant procedures were performed in 44 (41.1%) patients in the BAV group and in 339 (49.1%) patients in the TAV group (P = 0.123); surgery of the ascending aorta was necessary in 24 (22.4%) in the BAV group, compared with 29 (4.2%) in the control group (P < 0.001). The 5-year cumulative incidence of moderate-to-severe paravalvular regurgitation in the BAV group was 10.7% [95% confidence interval (CI): 4.2-20.7%] and 3.9% (95% CI: 2.4-6.1%) in the TAV group (P = 0.057). Reoperation with valve explantation due to non-structural valve dysfunction at 5 years was 2.8% (95% CI: 0.5-8.8%) in the BAV group, compared to 1.9% (95% CI: 1.0-3.2%) in the TAV cohort (P = 0.89). The overall long-term survival rate in the BAV group was 92% (95% CI: 81-97%) at 5 years and 88% (95% CI: 73-95%), at 10 years, significantly better compared to the TAV group (log-rank test P = 0.002). CONCLUSIONS: RD-AVR can be performed in patients with a BAV with convincingly medical outcomes. However, a trend to increased frequency of moderate-severe paravalvular regurgitation was observed at long-term follow-up. Consequently, a different surgical approach, compared to tricuspid valves, with distinctly specific technical- and anatomical considerations and requirements, is recommended.
引用
- Coti I, Werner P, Kaider A, et al. Rapid-deployment aortic valve replacement for patients with bicuspid aortic valve: a single-centre experience. Eur J Cardiothorac Surg. 2022. PMID: 35076066. doi:10.1093/ejcts/ezac017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。